INM News and Press, InMed Pharmaceuticals Inc. From 07/25/22

InMed Pharmaceuticals ( NASDAQ: INM ) on Monday said its phase 2 trial with its cannabinol-based cream for the treatment of skin disorder epidermolysis bullosa was recently expanded to include adolescents following a positive recommendation from a data safety board. INM st...

Phase 2 clinical trial recently expanded to include adolescents following independent review of early safety data First adolescent patient with EB enrolled into clinical trial and completed treatment International patent granted for the use of cannabinol for the treatmen...

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced its appointment of Michael Woudenberg as chief operating officer of the company, overseeing all day-to-day operations. Woudenberg previously...

InMed Pharmaceuticals ( NASDAQ: INM ) appointed Michael Woudenberg as its COO overseeing all day-to-day operations. He was earlier SVP, Chemistry, Manufacturing and Controls; he has been integral part of the executive team for the last four years, supporting mult...

VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces Michael Woudenberg...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com We’re starting the last day of trading this week with a breakdown of the biggest pre-market stock movers for Friday! News moving stocks this morning include a special purp...

InMed Pharmaceuticals ( NASDAQ: INM ) received a letter from Nasdaq for not meeting the minimum bid price of $1.00 per share required for continued listing. Company may be eligible for an additional 180 calendar days to regain compliance. The notice has no im...

VANCOUVER, British Columbia, July 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“ InMed ” or the “ Company ”) ( Nasdaq: INM ), a research, development, manufacturing corporation specializing in the commercialization of rare cannabinoids, an...

InMed Pharma (NASDAQ:INM +6.5%) said on Tuesday that a peer-reviewed study analyzed the effects of rare cannabinoids THCV, CBC, cannabigerol (CBG) and cannabigerolic acid (CBGA) on skin conditions. The researchers used a widely recognized in vitro model of human keratinocytes, and studie...

VANCOUVER, British Columbia, June 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that a peer-re...